Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCI-110 crossover placebo-controlled phase 2 study in adults with Tourette syndrome
MOH_2022-05-01_010768Phase 2Not yet recruiting
- Sponsor
- Neurothera Labs Inc.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dronabinol + palmitoylethanolamide, dronabinol and palmitoylethanolamide in Tourette syndrome (TS) (2 arms), sponsored by Neurothera Labs Inc. Primary endpoint: Efficacy, safety, and tolerability of SCI-110 versus placebo. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
dronabinol + palmitoylethanolamidedronabinolpalmitoylethanolamide
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on MOH_2022-05-01_010768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-01_010768.